|
시장보고서
상품코드
1623518
에피제네틱스 시장 규모 : 제품 유형별, 용도별, 최종사용자별, 지역별, 범위 및 예측Global Epigenetics Market Size By Product Type (Kits and Reagents, Instruments and Equipment), By Application (Oncology, Neurology), By End-User (Academic Research, Clinical Laboratories), By Geographic Scope And Forecast |
||||||
에피제네틱스 시장 규모는 2024년에 13억 달러로 평가되며, 2024-2031년 13.94%의 CAGR로 성장하며, 2031년에는 37억 달러에 달할 것으로 예측됩니다. 후성유전학은 DNA 염기서열의 변화를 수반하지 않는 유전적 유전자 발현의 변화를 연구하는 학문입니다. 이러한 변화는 DNA 메틸화, 히스톤 변형, 비암호화 RNA 분자 등 다양한 방법으로 발생할 수 있습니다. 후성유전학은 발달, 세포 분화, 환경 자극에 대한 반응 등 많은 생물학적 과정에서 중요합니다. 후성유전학은 후성유전학적 변형을 이해함으로써 새로운 치료법으로 이어질 수 있는 암 연구와 후성유전학적 프로파일링을 통해 치료 전략을 안내하는 맞춤형 의료 등의 분야에서 새로운 용도를 찾고 있습니다.
후성유전학은 특히 CRISPR 유전자 편집과 하이스루풋 시퀀싱과 같은 첨단 기술의 도입으로 상당한 진전을 이루고 있습니다. 이러한 발전은 후성유전학의 환경과 그 역동적인 특징에 대한 이해를 높이고, 연구자들이 복잡한 질병을 분자 수준에서 이해할 수 있도록 도와줄 것으로 보입니다.
이상한 후성유전학적 변화를 복구하는 것을 목표로 하는 후성유전학적 치료는 신경질환, 대사성 질환 등 다양한 질환에 대한 흥미로운 치료법을 제공합니다. 후성유전학에 대한 이해가 깊어짐에 따라 후성유전학은 의료 및 치료 중재 개발에서 점점 더 중요한 역할을 할 것으로 예상되며, 보다 맞춤화되고 성공적인 치료의 길을 열어줄 것으로 기대됩니다.
세계 후성유전학 시장을 형성하는 주요 시장 역학
주요 시장 성장 촉진요인
암 유병률 증가:
세계 암 유병률 증가는 후성유전학 시장의 중요한 촉진요인으로, WHO에 따르면 2020년 암으로 인한 사망자는 약 1,000만 명에 달할 것으로 예상되며, IARC는 2040년까지 2,840만 명이 새로 암에 걸릴 것으로 예측하고 있으며, 이는 47% 증가한 수치입니다. 암 발병률 증가는 연구자들이 유전자 발현의 변동에 기반한 보다 효과적인 표적 치료법을 찾고 있으므로 후성유전체 의약품과 진단에 대한 수요를 증가시키고 있습니다.
연구개발 투자 증가:
후성유전학 연구에 대한 자금 지원 증가가 시장 확대의 원동력이 되고 있습니다. 미국 국립보건원(NIH)에 따르면 후성유전학 연구 자금은 지난 10년간 85% 급증하여 2013년 5억 7,300만 달러에서 2022년 10억 6,000만 달러에 달할 것으로 예상하고 있습니다. 이러한 막대한 자금은 후성유전학 기반 의약품 및 진단 툴의 개발을 가속화하고 있습니다.
맞춤형 의료의 응용 확대:
에피제네틱스 시장은 맞춤형 의료의 동향에 의해 성장을 달성하고 있습니다. The tailored Medicine Coalition의 보고서에 따르면 FDA가 승인한 신약 중 맞춤형 의약품이 차지하는 비중은 2005년 5%에서 2018년 25%로 증가했습니다. 증가했습니다. 후성유전학적 바이오마커는 환자 개개인에 맞게 치료를 맞춤화하는 데 필수적이며, 후성유전학적 기술과 서비스에 대한 수요를 촉진하고 있습니다.
주요 과제
후성유전학적 메커니즘의 복잡성:
후성유전학적 조절에는 DNA 메틸화, 히스톤 변형, RNA 간섭 등 다양한 메커니즘이 관여하며, 이들은 모두 밀접하게 상호 작용합니다. 이러한 복잡한 시스템을 이해하는 것은 어렵고, 표적 의약품의 개발을 지연시키고 있습니다. 질병에서 다양한 시스템의 정확한 기능을 규명해야 하므로 연구를 방해하고 신약의 발견과 상용화 속도에 영향을 미치고 있습니다.
높은 연구개발비:
후성유전학에 기반한 의약품 및 진단약 개발에는 첨단 기술과 지식이 필요하며, 연구개발비용이 많이 소요됩니다. 최첨단 시퀀싱 기술, 생물정보학 툴, 임상시험에 소요되는 고비용은 중소 생명공학 기업에게 경제적 부담을 안겨줍니다. 그 결과, 기술 혁신은 자금력이 있는 연구기관에 국한되어 시장 확대가 지연되고 신규 기업의 진입을 방해하고 있습니다.
임상시험의 높은 실패율 :
많은 후성유전체 의약품이 임상시험에서 유효성과 안전성을 입증하지 못해 큰 감소율을 보이고 있습니다. 이러한 실패는 투자 의욕을 떨어뜨릴 뿐만 아니라 비용을 증가시키고 잠재적인 의약품의 승인을 지연시킵니다. 높은 실패율은 후성유전학적 경로를 실용적인 의약품으로 전환하는 것이 복잡하다는 것을 반영하고 있으며, 이는 시장의 진전을 늦추고 있습니다.
주요 동향 :
시퀀싱 기술의 발전 :
차세대 시퀀싱(NGS) 기술은 후성유전학적 변화를 유전체 수준에서 조사할 수 있는 능력을 크게 향상시켰습니다. 이러한 발전으로 DNA 메틸화 및 히스톤 변화를 보다 정확하게 검출할 수 있게 되어 보다 빠르고 정확한 조사가 가능해졌으며, NGS의 저비용화 및 효율성 향상으로 개인의 후성유전학적 프로파일에 기반한 맞춤형 의약품 개발이 촉진되어 후성유전학 시장의 성장을 가속화하고 있습니다. 성장을 가속화하고 있습니다.
맞춤형 의료에 대한 관심 증대
후성유전학은 개인의 유전적, 후성유전학적 프로파일에 맞는 치료를 가능하게 하므로 맞춤의료의 중요한 요소입니다. 맞춤형 후성유전학 치료는 암과 같은 질병과 관련된 특정 유전자 발현 변화를 표적으로 삼을 수 있으며, 치료 효과를 높이고 부작용을 줄일 수 있습니다. 헬스케어 산업이 개인 맞춤형 치료로 전환함에 따라 후성유전학적 진단 및 의약품에 대한 수요가 증가하고 있습니다.
노화와 후성유전학에 대한 관심 증가:
후성유전학은 노화 연구에서 점점 더 중요해지고 있으며, 노화에 따른 유전자 발현의 변화가 암과 신경장애를 포함한 다양한 질병에 영향을 미친다는 연구 결과가 발표되고 있습니다. 전 세계 인구가 고령화됨에 따라 후성유전학적 변화가 노화 과정에 어떤 영향을 미치는지, 그리고 의약품이 이러한 변화를 늦추거나 되돌릴 수 있는 가능성에 대한 이해가 중요해지면서 시장의 관심과 투자가 증가하고 있습니다.
Epigenetics Market size was valued at USD 1.30 Billion in 2024 and is projected to reach USD 3.70 Billion by 2031 , growing at a CAGR of 13.94% from 2024 to 2031. Epigenetics is the study of heritable changes in gene expression that do not entail modifications to the underlying DNA sequence. These alterations can occur through a variety of methods, including DNA methylation, histone modification, and non-coding RNA molecules, all of which can influence gene function and contribute to phenotypic variability. Epigenetics is important in many biological processes, including development, cellular differentiation, and reactions to environmental stimuli. Epigenetics is finding new applications in sectors such as cancer research, where understanding epigenetic modifications might lead to novel therapeutic methods, and personalized medicine, where epigenetic profiling can guide treatment strategies.
Epigenetics is set for considerable progress, particularly with the incorporation of cutting-edge technologies like CRISPR gene editing and high-throughput sequencing. These advancements will improve our grasp of the epigenetic landscape and its dynamic character, allowing researchers to unravel complicated disorders on a molecular scale.
Epigenetic therapies, which aim to repair aberrant epigenetic alterations, offer intriguing treatment options for a variety of ailments, including neurological disorders and metabolic diseases. As our understanding of epigenetics grows, it is expected to play an increasingly important role in developing healthcare and therapeutic interventions, paving the path for more tailored and successful treatments.
The key market dynamics that are shaping the global epigenetics market include:
Key Market Drivers:
Increasing Cancer Prevalence:
The increased global prevalence of cancer is a significant driver of the epigenetics market. According to the WHO, cancer killed roughly 10 million people in 2020, and the IARC projects 28.4 million new cases by 2040, a 47% rise. The increase in cancer incidence is driving up demand for epigenetic medicines and diagnostics, as researchers seek more effective, targeted treatments based on gene expression variations.
Rising Investment in Research and Development:
Increased funding for epigenetic research is driving market expansion. According to the National Institutes of Health (NIH), funding for epigenetics research has surged by 85% over the past decade, from $573 million in 2013 to $1.06 billion in 2022. This significant funding has accelerated the development of epigenetic-based medicines and diagnostic tools.
Growing Application in Personalized Medicine:
The epigenetics market is experiencing growth due to the trend towards personalized medicine. The tailored Medicine Coalition reported that tailored medicines accounted for 25% of all new pharmaceuticals approved by the FDA in 2018, up from 5% in 2005. Epigenetic biomarkers are critical for personalizing treatments to individual patients, which drives demand for epigenetic technology and services.
Key Challenges:
Complexity of Epigenetic Mechanisms:
Epigenetic regulation involves a variety of mechanisms, including DNA methylation, histone modification, and RNA interference, all of which interact intimately. Understanding these complicated systems is difficult, delaying the development of targeted medicines. The necessity to determine the precise function of various systems in diseases hampers research, affecting the rate at which new medicines are found and commercialized.
High Research and Development Costs:
Developing epigenetic-based medicines and diagnostics necessitates advanced technology and knowledge, which raises R&D costs. The high expense of cutting-edge sequencing technologies, bioinformatics tools, and clinical trials places a financial burden on smaller biotech enterprises. As a result, innovation is restricted to well-funded institutions, delaying market expansion and preventing the entry of new firms.
High Failure Rate in Clinical Trials:
Many epigenetic medicines fail to show efficacy or safety in clinical trials, owing to significant attrition rates. These failures not only discourage investment but also raise expenses and slow the approval of potential medicines. The high failure rate reflects the complexities of converting epigenetic pathways into practical medicines, which has slowed market advancement.
Key Trends:
Advancements in Sequencing Technologies:
Next-generation sequencing (NGS) technologies have considerably increased the ability to examine epigenetic changes at the genome-wide level. These developments enable more precise detection of DNA methylation and histone changes, resulting in faster and more accurate research. The lower cost and better efficiency of NGS are driving the development of tailored medicines based on an individual's epigenetic profile, hastening the growth of the epigenetics market.
Growing Focus on Personalized Medicine:
Epigenetics is an important component of personalized medicine as it allows for therapies that are matched to individual genetic and epigenetic profiles. Personalized epigenetic therapy can target specific gene expression alterations associated with diseases such as cancer, increasing treatment efficacy while lowering negative effects. As the healthcare industry shifts toward more personalized treatment, demand for epigenetic diagnostics and medicines is increasing.
Growing Interest in Aging and Epigenetics:
Epigenetics has grown increasingly important in aging research, with studies indicating that age-related changes in gene expression contribute to a variety of diseases, including cancer and neurological disorders. As the world's population ages, there is a rising emphasis on understanding how epigenetic modifications affect aging processes and how medicines may be able to slow or reverse these changes, generating market interest and investment.
Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.
Here is a more detailed regional analysis of the global epigenetics market:
North America:
North America continues to dominate the global epigenetics market, owing to considerable research investments and a high prevalence of epigenetic illnesses, particularly cancer. The NIH's funding for epigenetics research in the US has increased by 85%, from $573 million in 2013 to $1.06 billion in 2022. This initiative demonstrates the region's commitment to advancing epigenetic medicines and diagnostics. With roughly 2 million new cancer cases projected in the United States by 2023, demand for epigenetic-based treatments is increasing, as epigenetic modifications play an important role in cancer formation.
The region's robust biotechnology and pharmaceutical industries also drive innovation. In 2018, the US bioscience industry employed 1.87 million workers, allowing for the quick commercialization of epigenetic discoveries. The FDA's approval of many epigenetic treatments contributes to market growth. North America's early embrace of advanced technology such as next-generation sequencing, hastens epigenetics research and ensures its market dominance.
Asia Pacific:
The Asia Pacific epigenetics market is expanding rapidly, fueled by increased research funding and the rising prevalence of diseases with epigenetic connections, such as cancer. Regional R&D spending is expected to exceed $1.2 trillion by 2025, with a major amount dedicated to life sciences and biotechnology. Countries like China, which are predicted to see a huge increase in cancer incidence (from 4.57 million in 2020 to 6.67 million by 2040), are driving demand for epigenetic-based diagnostics and cures. This increase in investment and illness load is hastening the region's market expansion.
Furthermore, aging populations, notably in Japan, and supportive government programs, such as India's Genome India Project, are accelerating epigenetics research. Rising disposable income in the region, which has resulted in higher healthcare spending, is pushing up demand for innovative medical technologies such as epigenetic tools. The increased usage of next-generation sequencing technology, projected to reach $5.6 billion by 2026, is permitting more complex epigenetic investigations, establishing Asia Pacific as a significant player in the global epigenetics market.
The Global Epigenetics Market is Segmented on the basis of Product Type, Application, End-User, And Geography.
Based on Product Type, the market is bifurcated into Kits and Reagents, Instruments and Equipment, and Enzymes. The Kits and Reagents category is dominant due to their essential significance in research and diagnosis, since they are commonly employed for DNA methylation, histone modification, and chromatin accessibility studies. The fastest-growing area is Enzymes, which is being driven by rising demand for enzymes such as DNA methyltransferases and histone deacetylases in drug discovery and personalized medicine, particularly in cancer research and therapeutic development.
Based on Application, the market is segmented into Oncology, Neurology, and Developmental Biology. Oncology is the dominant segment, owing to the high frequency of cancer and the crucial significance of epigenetic changes in cancer genesis, diagnosis, and treatment. Epigenetic treatments, which target DNA methylation and histone modification, are commonly used in oncology. Neurology is the fastest-growing category, with research into epigenetic aspects in neurodegenerative disorders such as Alzheimer's and Parkinson's gaining traction, opening up new diagnostic and therapeutic possibilities.
Based on End-User, the market is segmented into Academic Research, Pharmaceutical and Biotechnology Companies, Clinical Laboratories, and Government Research Institutes. Pharmaceuticals and Biotechnology Companies dominate due to their essential role in creating epigenetic-based medicines, particularly for cancer and other chronic diseases. These companies make significant investments in research and development to create novel medications and diagnostic technologies. Academic Research is the fastest-growing category, driven by rising funding for fundamental and translational epigenetics research as universities and research institutes investigate new therapeutic targets and personalized medicine applications.
Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.